NCT06040008

Brief Summary

Changes in biology will be reflected by changes in the composition of Ribonucleic acid (RNA) in the blood. An example of that would be environmental changes, e.g. diet, acute illness, temperature. The main goal of this study is to study the impact of environmental changes in blood transcriptomics in healthy individuals over time.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 9, 2023

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

September 6, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

September 15, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 29, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 29, 2024

Completed
Last Updated

September 20, 2024

Status Verified

September 1, 2024

Enrollment Period

10 months

First QC Date

September 6, 2023

Last Update Submit

September 18, 2024

Conditions

Keywords

Healthy volunteers

Outcome Measures

Primary Outcomes (1)

  • study the impact of environmental changes in blood transcriptomics

    Changes in biology will be reflected by changes in the composition of Ribonucleic acid (RNA) in the blood. An example of that would be environmental changes, e.g. diet, acute illness, temperature.

    12 months

Secondary Outcomes (1)

  • different sample collection materials

    12 months

Study Arms (1)

healthy volunteers

Healthy status is defined by the absence of evidence of any active or chronic disease at the beginning of the study

Genetic: blood collection

Interventions

* 3 blood collections over a period of 6 weeks * V0 - Inclusion * V1 - 3 weeks ± 14 days * V2 - 3 weeks ± 14 days * 1 EDTA 4 ml tube, 1 PAXgene RNA tube 2,5 ml and drops of blood from finger-prick are taken at each visit * Clinical information obtained at each visit

healthy volunteers

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

healthy participants

You may qualify if:

  • Voluntary, informed consent is obtained from the subject before enrollment in the study
  • The subject is 18 years or older (≥18 years)
  • Healthy participants, as declared by the subject
  • Healthy status is defined by the absence of evidence of any active or chronic disease at the beginning of the study
  • Available to participate for the planned duration of the study for which the screening is being done

You may not qualify if:

  • The subject had any clinically significant disease
  • Any clinically relevant history or the presence of e.g., respiratory, renal, hepatic, gastrointestinal, hematological, lymphatic, neurological, cardiovascular, psychiatric, etc. chronic disease
  • Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
  • A condition in which repeated blood draws poses more than minimal risk for the subject such as hemophilia, other severe coagulation disorders or significantly impaired venous access
  • In the opinion of the investigator, subject is at high risk of non-compliance and is unsuitable in any other way to participate in this study
  • No informed consent obtained from the subject

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centogene GmbH

Rostock, Mecklenburg-Vorpommern, 18055, Germany

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Tobias Böttcher, MD

    CENTOGENE GmbH Rostock

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 6, 2023

First Posted

September 15, 2023

Study Start

May 9, 2023

Primary Completion

February 29, 2024

Study Completion

February 29, 2024

Last Updated

September 20, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

Locations